VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Evolving treatment landscape for myeloma: ADCs

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, discusses the emergence of antibody-drug conjugates (ADC) as a new class of treatment for multiple myeloma, including belantamab mafodotin (belamaf) and belamaf-based combinations. There are also novel ADCs undergoing pre-clinical and early clinical trials, such as MEDI2228. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Honoraria: Takeda, Abbvie, GSK
Consultancy: BMS, Janssen, GSK

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter